Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC-PsA 2: Icotrokinra in Biologic-experienced and Biologic-naive Psoriatic Arthritis
jRCT2011240063Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2025
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in psoriatic arthritis (PsA) and psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ACR20 response at Week 16. Started Jun 2025; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
psoriatic arthritis (PsA)psoriasis
Beyond the preview
Go deeper on jRCT2011240063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240063.